RXRX
$3.47-16.71%
Recursion Pharmaceuticals Inc.Stock · HealthcareRussell 2000 0.06%Nasdaq Composite 0.006%US Stock Market 0.003%Russell 3000 0.002%
Recursion Pharmaceuticals Inc. total returns by year (including dividends)
As of market close, Oct 16, 2026
Recursion Pharmaceuticals Inc. total returns by year (2022–2026)#
Calendar-year returns with each year's path and its dividend contribution (dividend return = total minus price return). Every year has a direct link you can bookmark or share.
| Year | Start price | End price | Path | Dividend | Total return |
|---|---|---|---|---|---|
| 2026YTD | $4.09 | $3.47 | 0.0% | -15.3% | |
| 2025 | $6.76 | $4.09 | 0.0% | -39.5% | |
| 2024 | $9.86 | $6.76 | 0.0% | -31.4% | |
| 2023 | $7.71 | $9.86 | 0.0% | +27.9% | |
| 2022 | $17.13 | $7.71 | 0.0% | -55.0% |
- Annualized
- -34.0%
- 2022–2026
- Average year
- -24.5%
- 4 full years
- Best year
- +27.9%
- 2023
- Worst year
- -55.0%
- 2022
- Positive years
- 1/4
- 25% up
Annualized (CAGR)
-34.0%
2022–2026
Average year
-24.5%
4 full years
Best year
+27.9%
2023
Worst year
-55.0%
2022
Positive years
1/4
25% up
Total return by period#
Annual
-40%-20%0%20%40%
2022-55%'22
2023+28%'23
2024-31%'24
2025-39%'25
2026-15%'26
Methodology#
Total returns, dividends reinvested, measured on RXRX. Annualized return is the compound annual growth rate; the current year is year-to-date. Past performance does not predict future returns.
FAQ#
- What is Recursion Pharmaceuticals Inc.'s average annual return?
- Since 2022, Recursion Pharmaceuticals Inc. (RXRX) has returned about -34.0% a year (the compound annual growth rate) and an average calendar-year return of -24.5%.
- What were Recursion Pharmaceuticals Inc.'s best and worst years?
- Over 2022–2026, the best year was 2023 (+27.9%) and the worst was 2022 (-55.0%).
- How often is Recursion Pharmaceuticals Inc. up in a year?
- 1 of the 4 full years since 2022 were positive — about 25% of the time.
More on Recursion Pharmaceuticals Inc.
Annual returns for: S&P 500 · S&P 500 Equal Weight · US Stock Market · Nasdaq-100